Targeting of IGF-1R signalling in preclinical tumour models has suppressed growth of prostate cancer cells, induced apoptosis in vitro and in vivo and has sensitised cancer cells to conventional chemotherapeutic treatment and irradiation (Burtrum et al, 2003). The gene discussed is IGF1R; the disease is prostate cancer.